<DOC>
	<DOCNO>NCT00712049</DOCNO>
	<brief_summary>Dyslipidaemia characterize low plasma level high-density lipoprotein cholesterol ( HDL-c ) , elevate triglyceride increase low density lipoprotein ( LDL-c ) particle , unequivocally establish important cardiovascular risk factor . While statin effective reduce plasma level LDL-c , drug modest effect raise HDL-c ( typically less 10 % ) , even aggressive statin therapy . However , increase evidence suggest low HDL-c might least relevant high LDL-c promoting development progression atherosclerosis . The beneficial effect raise HDL-c clinical outcome already demonstrate several study . Nicotinic acid potent agent available raise plasma level HDL-c 29 % clinically recommended dos , substantially lower triglyceride LDL-c . Furthermore , nicotinic acid also potent lipid lower agent available reduces Lp ( ) , independent marker cardiovascular risk . In recent study patient coronary artery disease 21 % increase HDL-c 13 % decrease triglyceride , beneficial effect lipid status may contribute stabilization regression carotid intima-media-thickness ( IMT ) .The impact patient advance atherosclerosis like peripheral artery disease ( PAD ) unknown . The investigator hypothesize nicotinic acid addition statin therapy may inhibit progression peripheral arterial atherosclerosis . Therefore , aim present randomize control trial investigate effect nicotinic acid ( daily dose start 500 mg , 2000mg ) addition simvastatin ( 40 mg daily ) versus simvastatin ( 40mg daily ) monotherapy patient low serum HDL-C level PAD respect change carotid femoral IMT , change patients´ lipid status occurrence major adverse cardiovascular event ( MACE ) .</brief_summary>
	<brief_title>Effects Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone Carotid Femoral Intima-Media Thickness Patients With Peripheral Artery Disease ( NASCIT )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>PAD define ABI ≤0.9 &gt; 1.3 patient low serum HDL cholesterol level ( &lt; 45mg/dL men , &lt; 55 mg/dL woman ) Elevated liver enzyme ( 2 time normal level ) Skeletal muscle myopathy elevate serum CK level Allergy hypersensibility either statins nicotinic acid Women childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>intima-media-thickness</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>progression atherosclerosis</keyword>
	<keyword>peripheral artery disease</keyword>
	<keyword>major cardiovascular event</keyword>
</DOC>